Precious clinical samples often force trade-offs between genetic and epigenetic analyses. Conventional epigenetic sequencing adds further compromises by either combining 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) into a single modC signal, or measuring only one modification type, obscuring important biology. biomodal 6-base sequencing is designed to overcome these limitations by enabling simultaneous variant detection and independent quantification of both 5mC and 5hmC from a single sample and as little as 5ng DNA.

What you'll learn

In this webinar, we demonstrate how 6-base sequencing expands both the analytical and biological insight that can be obtained from precious samples. We review low-frequency genetic variant detection and benchmark the epigenetic calling accuracy of our duet assays.

We will then show how independent measurements of 5mC and 5hmC can influence biological interpretation. Alternate approaches can miss biologically meaningful signals when opposing 5mC and 5hmC changes are collapsed into a single methylation readout, masking differential methylation and activation-linked regulatory states. Finally, we will discuss how integrating genetic, 5mC and 5hmC information from the same dataset can improve biomarker discovery and generate richer biological insight from limited material.

The takeaway

By combining highly accurate variant detection with independent measurement of 5mC and 5hmC, you can get it all with duet in a single assay. Recover genetic and epigenetic insights that would otherwise require multiple workflows or remain hidden entirely. The result is a more complete view of biology and greater value from every precious sample.

The speaker:

Tom Charlesworth

Director, Market Strategy and Corporate Development

This webinar was originally broadcast on October 14, 2026.